Introduction
============

Cervical cancer, the fourth most common cancer in women worldwide, with relatively high numbers occurring in developing countries, including China, has the major etiological factor which is persistent infection of oncogenic Human papillomavirus (HPV) ([@b1-mmr-17-05-7131],[@b2-mmr-17-05-7131]).

The HPV genome is a small double-stranded circular DNA molecule of 8,000 base pairs (bp) which contains three regions: i) 4,000 bp region encoding 6 early proteins participating in viral replication and cell transformation, including 3 regulatory proteins (E1, E2 and E4) and 3 oncoproteins (E5, E6 and E7); ii) 3,000 bp region encoding the structural proteins of the virus, including major capsid protein L1 and the minor capsid protein L2; and iii) 1,000 bp long control region (LCR) that contains the origin of viral DNA replication and transcriptional regulatory elements ([@b3-mmr-17-05-7131]).

Any two HPV strains may be classified into types, subtypes or variants according to the difference rate between their L1 sequences that is the difference rate \>10%, between 2 and 10% or \<2% ([@b4-mmr-17-05-7131]). Currently, \>200 HPV types have been fully characterized (<http://www.hpvcenter.se/html/refclones.html>), and the International Agency for Research on Cancer defined 12 HPV types as oncogenic or potentially carcinogenic groups ([@b5-mmr-17-05-7131]). Except for HPV51 (belongs to a-5) and HPV-56 (belongs to a-6), others of these carcinogenic types are phylogenetically clustered with a-7 (HPV-18, HPV-39, HPV-45, HPV-59) or a-9 (HPV-16, HPV-31, HPV-33, HPV-35, HPV-52, HPV-58) ([@b6-mmr-17-05-7131]).

HPV-56 is an oncogenic HPV type, which was initially described in the United States in 1989 ([@b7-mmr-17-05-7131]). Globally, HPV-56 accounts for \<1% of cervical cancer cases ([@b1-mmr-17-05-7131]) However, compared with the rest of the world, the prevalence of HPV-56 is remarkably high in Asia, particularly in China ([@b8-mmr-17-05-7131],[@b9-mmr-17-05-7131]). According to a recent study from China\'s largest KingMed Laboratory (Guangzhou, Guangdong, China), from January 2011 to June 2014, the detection rate of HPV-56 among the 51,345 samples was ranked fourth below the three most highly detected types, HPV-52, HPV-16, and HPV-58 ([@b10-mmr-17-05-7131]). Additionally, another previous study on the prevalence and distribution of HPV in 37 cities in China revealed that HPV-56 infection rate is 6.09%, ranking fifth from 2,580 high risk HPV-positive samples ([@b11-mmr-17-05-7131]). These findings are similar to those observed in southwest China in the past two years ([@b12-mmr-17-05-7131]).

Previous studies suggested that variants of the same HPV type are biologically distinct and may result in differing pathogenic risks ([@b13-mmr-17-05-7131]--[@b15-mmr-17-05-7131]). The viral LCR region as the primary recognition site of the transcription factor, variations in this region may affect virus replication rates and the transcriptional activity ([@b16-mmr-17-05-7131]). When considering the E6 and E7 oncoproteins, one or more amino acid changes may potentially alter cellular immortalization, transformation and carcinogenesis ([@b17-mmr-17-05-7131],[@b18-mmr-17-05-7131]). Changes in the L1 amino acid sequence, which contains sequences important for conformation of viral neutralization-relevant epitopes, may affect viral antigenicity or influence the effectiveness of viral infection ([@b19-mmr-17-05-7131]). Currently, the information available on sequence variation in HPV-16, HPV-18, HPV-52, and HPV-58 is relatively comprehensive ([@b20-mmr-17-05-7131]--[@b23-mmr-17-05-7131]). However, data on HPV-56 variants is limited and sequence variations of HPV-56 in the Asian population remain to be elucidated ([@b24-mmr-17-05-7131],[@b25-mmr-17-05-7131]). Therefore, the aim of the present study was to detect sequence variations within LCR, E6, E7, and L1 of HPV-56 in women from southwest China. The current study may improve the understanding of the viral persistence, transmission and oncogenic potential. Furthermore, identifying novel variants of HPV-56 may assist in the design of vaccines and development of diagnostic probes for specific populations.

Materials and methods
=====================

### Ethics statement

The present study was approved by the Education and Research Committee and the Ethics Committee of Sichuan University (Chengdu, China). Prior to sample collection, written informed consent was obtained from the patients and study subject privacy was carefully protected.

### Sample collection

From January 2014 to January 2016, 7,707 cervical swabs were collected from female patients (age range, 18--65 years) that received HPV infection screening at the following maternity hospitals in Sichuan, China: Sichuan Reproductive Health Research Center Affiliated Hospital, The Angel Women\'s and Children\'s Hospital, The Chengdu Western Hospital Maternity Unit, The Peoples\' Hospital of Pengzhou, Jinjiang Maternity and Child Health Hospital, Chengdu Zongnan Gynecology Hospital and Chengdu Songziniao Sterility Hospital. Samples were placed in preservative buffer (Yaneng Bioscience Co., Ltd., Shenzhen, China) and stored at −20°C.

### HPV DNA detection and typing

Following sample collection, the viral genomic DNA was extracted and genotyped using the human papillomavirus genotyping kit for 23 types (Yaneng Bioscience Co., Ltd.) according to the manufacturer\'s protocol. This kit is based on a reverse dot blot principle and is able to classify 23 HPV genotypes, including the 18 high-risk, the probable high-risk types (16, 18, 31, 33,35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 83, and MM4), and the 5 low-risk types (6, 11, 42, 43, and 44). A total of 101 of HPV-56 positive samples DNA were detected and subsequently stored at −20°C.

### PCR amplification and variant identification

The LCR fragment was amplified using specific primers as previously described ([@b24-mmr-17-05-7131]). The complete genes of E6, E7 and L1 primers were designed using Primer Primier version 5.0 (Premier Biosoft, Palo Alto CA, USA; <http://www.premierbiosoft.com/>) ([@b26-mmr-17-05-7131]) based on the HPV-56 GenBank reference sequences X74483 (accession no. X74483; [www.ncbi.nlm.nih.gov/nuccore/X74483](www.ncbi.nlm.nih.gov/nuccore/X74483)) and listed in [Table I](#tI-mmr-17-05-7131){ref-type="table"}. The primers were synthesized by Sangon Biotech Co., Ltd., (Shanghai, China).

Each 25 µl PCR reaction contained 3 µl of extracted DNA (10--100 ng), 2.5 mM 10X PCR buffer (Mg^2+^) (Beijing TransGen Biotech Co., Ltd., Beijing, China), 2.5 mM dNTPs (Beijing TransGen Biotech Co., Ltd.), 2U Taq DNA polymerase (Sangon Biotech Co., Ltd.) and 90 pmol of each primer (Sangon Biotech Co., Ltd.). The PCR conditions were as follows: Initial denaturation at 95°C for 5 min, followed by 35 amplification cycles, with each cycle including a 45 sec denaturation step at 94°C, 1 min annealing step at a primer specific temperature, and a 1 min elongation step at 72°C, the process was completed with a final 10 min extension step at 72°C. The annealing temperatures for the PCR primer sequences of the selected genes are presented in [Table I](#tI-mmr-17-05-7131){ref-type="table"}.

Following PCR amplification, electrophoresis was performed to separate the products, using 2% agarose gel (Sangon Biotech Co., Ltd.) stained by GeneGreen (Tiangen Biotech Co., Ltd., Beijing, China) nucleic acid dye and the products were detected under ultra violet light. Target products were sequenced by Sangon Biotech Co., Ltd. (Shanghai, China) and the data were confirmed by repeating the PCR amplification and sequence analysis at least twice.

The sequences were subsequently analyzed by NCBI Blast ([blast.ncbi.nlm.nih.gov/Blast.cgi](blast.ncbi.nlm.nih.gov/Blast.cgi)) and DNAMAN version 5.2.2 (Lynnon Biosoft LLC, San Ramon, CA, USA). HPV-56 nucleotide positions were numbered according to the reference sequence X74483. Only when the LCR-E6-E7-L1 were amplified and sequenced simultaneously, was the resulting sequence selected for subsequent analyses.

### Phylogenetic trees analysis

Phylogenetic trees of HPV-56 LCR-E6-E7 and L1 were constructed with the maximum-likelihood trees method by Molecular Evolutionary Genetics Analysis version 6 software using Kimura\'s two-parameter model, respectively. The reference viral sequences EF177181, EF177180, EF177179, EF177178, KU298915, KU298916, KU298918, KU298917, KU298919, EF177176, EF177177, collected from the GenBank sequence database were used to construct the distinct phylogenetic branches. The tree topology was evaluated by using bootstrap resampled 1,000 times as previously described ([@b27-mmr-17-05-7131]). Numbers above the branches indicate the bootstrap values that are \>70%.

### Sequence analysis

The secondary structure was predicted with the PSIPRED server ([bioinf.cs.ucl.ac.uk/psipred/](bioinf.cs.ucl.ac.uk/psipred/)), which provides a simple and accurate secondary structure prediction method as previously described ([@b28-mmr-17-05-7131]). The prediction of the damaging effect of missense mutation to protein structure and function was performed using PolyPhen-2 software ([genetics.bwh.harvard.edu/pph2/](genetics.bwh.harvard.edu/pph2/)) ([@b29-mmr-17-05-7131]).

The MATCH 1.0 server ([www.gene-regulation.com/pub/programs.html\#match](www.gene-regulation.com/pub/programs.html#match)) ([@b30-mmr-17-05-7131]) was used to search within the LCR of HPV-56 for potential binding sites for cellular and viral transcriptional factors. Various transcriptional factors were identified, including AP-1, E2, GRE, NF-1, Oct-1, TATA, YY1, C/EBP, Sp1, SRY, AML-1a and c-Myc/c-Max.

### Selective pressure analysis

To estimate for positive selection at particular sites of the HPV-56 E6-E7 and L1 gene sequences, the *codeml* program in the Phylogenetic Analyses by Maximum Likelihood (PAML) version 4.8 package was used to perform likelihood ratio tests to infer nonsynonymous and synonymous nucleotide divergence for coding regions by the method of Nei and Gojobor ([@b31-mmr-17-05-7131]).

Results
=======

### Characteristics of HPV-56 prevalence in southwest China in the span of 2 years

During the period of January 2014 to January 2016, the overall prevalence of detectable HPV infection was 31.27% (2,407/7,707) and 21.42% (1,651/7,707) samples were high-risk HPV type and 9.85% (759/7,707) were low-risk HPV type. From the HPV-positive women involved in the present study, the most commonly detected high-risk HPV genotype was HPV-16 (336, 13.94%), followed by HPV-52 (258, 10.71%), HPV-58 (254, 10.54%) and HPV-33 (132, 5.48%). HPV-56 ranked fifth (101, 4.19%). Additional high-risk HPV genotypes were listed in descending order of priority as follows: HPV-18, −51, −53, −68, −66, −31, −39, −35, −45, −73, −83 and MM4 ([Fig. 1](#f1-mmr-17-05-7131){ref-type="fig"}).

### HPV-56 LCR-E6-E7 sequence variation

From the 101 samples which tested positive for HPV-56, 75 (75.25%) LCR-E6-E7-L1 sequences were amplified by PCR for variant analysis. The remaining 26 (25.75%) sequences were not obtained due to unsuccessful PCR.

All 75 HPV-56 LCR-E6-E7 isolates showed nucleotide variation when compared with the HPV-56 reference sequence (GenBank: X74483). The isolates were divided into 23 different groups denoted as 56SE01-56SE23. And these sequences were published with GenBank accession codes from KX645742 to KX645764.

From the HPV-56 LCR sequences, 18 point substitutions were detected, 11 of which were located in putative transcriptional factors binding sites and four substitutions (T7485C, T7581C, A7628C and T7800G) were present in all isolates. In addition, a 42 bp deletion and a 19 bp deletion were observed, leading to loss of a putative binding site for the YY1 transcriptional factor ([Table II](#tII-mmr-17-05-7131){ref-type="table"}).

A total of 18 single nucleotide changes occurred in the E6-E7 sequence, with 11/18 (61.11%) being non-synonymous substitutions and 7/18 (38.89%) being synonymous mutations. The sequence variability of E6 was lower than that of E7. The average probability of a nucleotide sequence deviation from the prototype was 6.2 substitutions per 1,000 bp for E6 and 6.4 substitutions per 1,000 bp for E7 ([Table II](#tII-mmr-17-05-7131){ref-type="table"}). Three amino acid mutations occurred in sequences encoding the α-helix, and five mutations (four non-synonymous) were observed in sequences encoding the β-sheet ([Table II](#tII-mmr-17-05-7131){ref-type="table"}). Additionally, PolyPhen-2 analysis predicted a Q77H/Y mutation of E7 to be 'possibly damaging' with a score of 0.702/0.610 on the HumVar model ([Fig. 2](#f2-mmr-17-05-7131){ref-type="fig"}). Mutations generating a frame shift or a premature stop codon were not observed.

### Phylogenetic analysis of HPV-56 LCR-E6-E7 sequences

Phylogenetic analysis based on HPV-56 LCR-E6-E7 1,259 bp nucleotide sequences was performed including 23 isolates in the current study, accompanied by 12 reference sequences. Based on whole genome study and the topology, two distinct branches were formed ([Fig. 3](#f3-mmr-17-05-7131){ref-type="fig"}) ([@b32-mmr-17-05-7131]). A total of 9 isolates in the current study (56SE01-S6SE09) were classified into the A variant lineage. The remaining 14 isolates (56SE10-S6SE23) were classified into the B variant lineage.

### HPV-56 L1 sequence variation

The nucleotide variation rate of HPV-56 L1 was 100% among the 75 HPV-56 isolates when compared with the HPV-56 reference sequence (GenBank: X74483). The L1 isolates were divided into 16 different groups denoted as 56HL01-56HL16 ([Table III](#tIII-mmr-17-05-7131){ref-type="table"}). And these sequences were published in GenBank with the accession codes KX645765-645780.

A total of 24 single nucleotide changes were identified in the 1,605 bp L1 sequence, 6 (33.33%) substitutions were non-synonymous mutations and 18 (66.67%) substitutions were synonymous mutations and G64554T was present in all samples analyzed ([Table III](#tIII-mmr-17-05-7131){ref-type="table"}). The average probability of a nucleotide sequence deviation from prototype was 4.04 substitutions per 1,000 bp for L1. No non-synonymous mutation was observed in the HPV-56 L1 sequences encoding the a-helix. 8 mutations (one non-synonymous) were observed in the sequences encoding the b sheet ([Table III](#tIII-mmr-17-05-7131){ref-type="table"}). In addition, PolyPhen-2 analysis predicted that K116M and N126D mutations of L1 were 'probably damaging' on HumVar model with the score of 0.975 and 0.918, respectively ([Fig. 4](#f4-mmr-17-05-7131){ref-type="fig"}). No frame shift and premature stop caused by mutations were observed.

### Phylogenetic analysis of HPV-56 L1 sequences

Phylogenetic analysis based on HPV-56 L1 1,605 bp nucleotide sequences was performed including 16 isolates in the current study, accompanied by 12 reference sequences. Based on whole genome study and the topology, 2 distinct branches were formed ([Fig. 5](#f5-mmr-17-05-7131){ref-type="fig"}) ([@b32-mmr-17-05-7131]). A total of 8 isolates in the current study (56HL01-S6HL08) were classified into the A variant lineage. The remaining 8 isolates (56HL09-S6HL18) were classified into the B variant lineage.

### Selective pressure analysis of HPV 56 E6-E7 and L1 sequences

PAML software was used to estimate the selective pressure of HPV-56. Positive selection for E6-E7 and L1 was identified and has been presented in [Tables IV](#tIV-mmr-17-05-7131){ref-type="table"} and [V](#tV-mmr-17-05-7131){ref-type="table"}, respectively. In addition, there was no evidence of negative selection in the sequence alignment of these genes (P\<0.1).

Discussion
==========

When considering the association between HPV and cervical cancer, HPV-16 and HPV-18 are the most frequent worldwide, with HPV-56 only accounting for a small proportion of the infections worldwide, with no available commercial vaccines ([@b33-mmr-17-05-7131]). However, the prevalence of high-risk HPV types differs greatly among different countries and regions. Previous studies have revealed a high detection rate of the HPV-56 strain among Chinese women ([@b9-mmr-17-05-7131]--[@b11-mmr-17-05-7131]). The purpose of the present study was to determine a ranking of HPV type prevalence and to demonstrate the importance and significance of HPV-56 in southwest China.

Previous studies have demonstrated that specific intratypic HPV genome variations may affect the virus infectivity, pathogenicity, oncogenicity, viral particle assembly and host immune response ([@b15-mmr-17-05-7131],[@b34-mmr-17-05-7131]). In the current study, the genetic variability of LCR, E6, E7 and L1 genes of HPV-56 in southwest China were analyzed. Additionally, phylogenetic trees were constructed for all variant strains and selection pressures of the E6, E7, and L1 genes were estimated.

The binding affinity of the cellular and viral transcriptional factor may be influenced by nucleotide variation within LCR ([@b35-mmr-17-05-7131]). Some of the mutations identified in the LCR in the present study are embedded in the putative binding sites for YY1, SRY, NF-1, TATA and C/EBP transcription factors. These mutations may affect the binding affinity of transcriptional factor and the transcription of the downstream E6 and E7 oncogenes; however, it remains to be determined by *in vitro* studies. When compared with a previous study, changes at positions 7,485, 7,504, 7,546, 7,582, 7,589, 7,678, 7,741, 7,781 and 7,796 of LCR, to the best of our knowledge, were described for the first time in the present study, and a new 19 bp deletion was not described previously ([@b14-mmr-17-05-7131]).

The early expressing proteins E6 and E7 of high-risk HPV are the primary oncoproteins involved in human epithelial cell immortalization and transformation due to their ability to inactivate p53 and pRb proteins, respectively ([@b36-mmr-17-05-7131],[@b37-mmr-17-05-7131]). In addition, amino acid mutation of E6/E7 genes may influence host immunologic responses ([@b38-mmr-17-05-7131]). Therefore, studies on the genetic variability in HPV E6/E7 may provide important basic data for future research on viral molecular mechanisms and contribute to the design of therapeutic vaccines, which target these proteins ([@b39-mmr-17-05-7131]). In the current study, 11/18 amino acid mutations identified in E6/E7 were non-synonymous, except for A141C, T158C and A263C, all the remaining mutations were described, to the best of our knowledge, for the first time in the current study. S14R and K54N of E6 amino acid substitutions were apparently associated and were simultaneously found in 47 isolates. It is of note that the present study identified that the E7 variation frequency is higher than E6 variations, similar to findings in the HPV-58 type ([@b40-mmr-17-05-7131]). Variants of the Q77H/Y changes of E7 was analyzed using PolyPhen-2 with results of 'possibly damaging', at the same time, the variant occurred in the E7 β-sheet, which may influence E7 structure.

Overall, the L1 major capsid protein may be used to inform the design of prophylactic vaccines and main components virus-like particles (VLPs) that induce high levels of neutralizing antibodies ([@b19-mmr-17-05-7131]). Additionally, conformational epitopes of HPV are primarily located in hypervariable immuno-dominant regions (BC, DE, EF, FG and HI loops). Therefore, previous studies demonstrated that polymorphisms in the L1 gene may have a critical role in the structure of the capsid protein, VLPs assembly and recognition epitopes ([@b41-mmr-17-05-7131]--[@b43-mmr-17-05-7131]). The nucleotide changes detected at positions 6,826 and 6,880 of HPV-56 L1 gene were previously described ([@b25-mmr-17-05-7131]); however, to the best of our knowledge the remaining mutations at other positions are described for the first time in the present study. Variants of K116M and N126D were analyzed using PolyPhen-2 and the mutation was identified as 'probably damaging'. Additionally, C19Y is located in the sequences encoding the b sheet, those variants may affect L1 structure.

In terms of phylogenetics, the current known HPV types have high diversity. According to the maximum-likelihood trees topology constructed by the current study and the reference strains, the strains are distributed in two clusters, not in one single cluster ([@b32-mmr-17-05-7131]). Selective pressure analysis revealed that the majority of the identified HPV amino acid changes were of positive selection, which indicated that these mutations were beneficial for HPV to accommodate the environment.

In summary, the current study reported the prevalence of HPV-56 and sequence variations in the LCR, E6, E7 and L1 genes of HPV-56 isolates from southwest China. Some of the variations identified in LCR are located within binding sites of transcriptional factors. In addition, the majority of nucleotide changes were described for the first time by the current study. To the best of our knowledge, this was the first comprehensive study to assess genetic variation of HPV-56 in southwest China. The present study provided important basic data for further research on viral molecular mechanisms and future development of diagnostic probes and therapeutic vaccines.

The authors would like to thank the following hospitals for the sample collection: Sichuan Reproductive Health Research Center Affiliated Hospital, The Angel Women\'s and Children\'s Hospital, The Chengdu Western Hospital Maternity Unit, The Peoples\' Hospital of Peng Zhou, Jinjiang Maternity and Child Health Hospital, Chengdu Zongnan Gynecology Hospital and Chengdu Songziniao Sterility Hospital.

Funding
=======

The present study was funded by the Institute of Medical Genetics, College of Life Science, Sichuan University, Chengdu, China.

Availability of data and materials
==================================

All data generated or analysed during this study are included in this published article and GeneBank.

Authors\' contributions
=======================

YJ and XD conceived and designed the study. YJ, TW, ZC, JX, XM, MC and HC performed the experiments. ZC and JX analyzed the data. YJ and TW were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

The present study was approved by the Education and Research Committee and the Ethics Committee of Sichuan University (Chengdu, China; approval number SCU20100196494).

Consent for publication
=======================

Prior to sample collection, written informed consent was obtained from the patients or their guardians, and patient/study subject privacy was carefully protected.

Competing interests
===================

The authors declare that they have no competing interests.

![Detection rates of the 23 types of HPV in the 7,707 women sampled. HPV, human papillomavirus.](MMR-17-05-7131-g00){#f1-mmr-17-05-7131}

![Predicted of HPV-56 E7 Q77H/Y substitution the pathogenicity by PolyPhen-2. Pathogenicity of (A) HPV-56 E7 Q77H and (B) HPV-56 E7 Q77Y substitution. HPV, human papillomavirus.](MMR-17-05-7131-g02){#f2-mmr-17-05-7131}

![Maximum-likelihood trees of LCR-E6-E7 of HPV-56. The maximum-likelihood tree of HPV-56 variants based on LCR-E6-E7 combined sequences. Sequences from the present study are labeled in black, the remaining are standard sequences used for alignment. The numbers above the branches indicate the bootstrap values \>70%.](MMR-17-05-7131-g03){#f3-mmr-17-05-7131}

![Predicted of HPV-56 L1 K116M and N126D substitutions the pathogenicity by PolyPhen-2. The pathogenicity of (A) HPV-56 L1 K116M and (B) HPV-56 L1 N126D substitution. HPV, human papillomavirus.](MMR-17-05-7131-g04){#f4-mmr-17-05-7131}

![Maximum-likelihood trees of L1 of HPV-56. The maximum-likelihood tree of HPV-56 variants based on L1 sequences. Sequences from the present study are labeled in black, the remaining are standard sequences used for alignment. The numbers above the branches indicate the bootstrap values \>70%.](MMR-17-05-7131-g05){#f5-mmr-17-05-7131}

###### 

Primers used for the molecular characterization of human papillomavirus-56 E6, E7 and L1 long control regions.

  Gene   Direction   Sequence 5′-3′                 Primer position   Product size, bp   Annealing Temperature, °C
  ------ ----------- ------------------------------ ----------------- ------------------ ---------------------------
  LCR    Forward     TGTGTCATTATTGTGGCTTTTGTTTTGT   7323              603                57
         Reverse     AGCTGCCTTTTATATGTACCGTTTTC     81                                   
  E6     Forward     ATTGGGAGTGACCGAAAAGG           26                803                58
         Reverse     ACAACACGCAGGTCCTCTTT           828                                  
  E7     Forward     GCTACAGATGTCAAAGTCCG           444               542                57.5
         Reverse     GCCTCTACTTCAAACCATCC           985                                  
  L1-1   Forward     GCCCCTTTAGGTAATGTGTGG          5418              943                59
         Reverse     CCACATAGAATCACCATAGGCAT        6360                                 
  L1-2   Forward     ATGATAGACACAGGATTTGGCG         6217              948                58
         Reverse     ATACAACACACAAACACAGTTACAC      7164                                 

###### 

Nucleotide sequence variations at long control regions-E6-E7 of 23 HPV-56 isolates.

![](MMR-17-05-7131-g01)

(−), conserved nucleotides with respect to the reference sequence; (.), a nucleotide deletion. Letters indicate variation in position. D1, deletion of 19 bp (7,509--7,527) among HPV-56 isolates; D2, deletion of 42 bp (7,492--7,533). S, Sheet; H, Helix; HPV, human papillomavirus.

###### 

Nucleotide sequence variations at L1 of 16 HPV-56 isolates.

                     L1                                                                                                                                                             
  ------------------ ---------- ---------- ---- ---------- ---- ---- ---- ---- ----------- ---- ----------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----------- ----
  Ref                C          G          A    A          A    A    G    A    A           G    A           A    A    G    G    T    T    A    T    C    A    A    G    A           
  56HL01             --         --         --   --         --   --   --   --   --          --   G           --   --   A    T    --   G    --   --   --   --   --   --   --          14
  56HL02             --         --         --   --         --   --   --   --   --          --   G           --   --   A    T    --   G    --   --   --   --   C    --   --          1
  56HL03             --         --         --   --         --   --   --   --   T           --   G           --   --   --   T    --   --   --   --   --   --   C    --   --          1
  56HL04             --         --         --   --         --   --   --   --   --          --   G           --   --   --   T    --   --   --   --   --   --   C    --   --          4
  56HL05             --         --         --   --         --   --   --   --   --          --   G           --   --   --   T    --   --   --   --   --   --   T    --   --          2
  56HL06             --         --         --   --         --   --   --   --   --          --   G           --   --   --   T    --   --   --   --   --   --   --   --   --          2
  56HL07             T          --         --   C          --   --   A    --   --          --   --          --   --   --   T    --   --   G    --   --   --   --   --   --          1
  56HL08             T          --         --   C          --   --   --   --   --          --   --          --   --   --   T    --   --   G    --   --   --   --   --   --          1
  56HL09             --         --         --   --         --   G    --   --   --          A    --          G    --   --   T    G    --   --   --   --   --   --   --   --          4
  56HL10             --         --         --   --         --   G    --   --   --          A    --          G    --   --   T    G    --   --   --   T    --   --   --   --          2
  56HL11             --         A          G    --         --   G    --   --   --          --   --          G    --   --   T    G    --   --   --   T    --   --   A    --          1
  56HL12             --         --         --   --         --   G    --   --   --          A    --          G    --   --   T    G    --   --   --   T    --   --   A    G           28
  56HL13             --         --         G    --         --   G    --   --   --          A    --          G    --   --   T    G    --   --   --   T    --   --   A    G           1
  56HL14             --         --         --   --         G    G    --   --   --          A    --          G    G    --   T    G    --   --   --   T    C    --   A    G           1
  56HL15             --         --         --   --         --   G    --   G    --          A    --          G    --   --   T    G    --   --   --   T    --   --   A    G           11
  56HL16             --         --         --   --         --   G    --   G    --          A    --          G    --   --   T    G    --   --   C    T    --   --   A    G           1
                                                                                                                                                                                    
                     **P13L**   **C19Y**   --   **E43D**   --   --   --   --   **K116M**   --   **N126D**   --   --   --   --   --   --   --   --   --   --   --   --   **K510R**   
                                                                                                                                                                                    
  Second structure   --         S          S    --         S    S    S    S    --          --   --          --   --   --   --   S    S    --   --   --   --   --   --   --          

(−), conserved nucleotides with respect to the reference sequence; (.), a nucleotide deletion. Letters indicate variation in position. S, Sheet; H, Helix. HPV, human papillomavirus.

###### 

Site-specific tests for positive selection on human papillomavirus-56 E6-E7.

  Models   InL        Parameters estimates                           2Δl              E6 positively selected sites                                                                                                                                    E7 positively selected sites
  -------- ---------- ---------------------------------------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  M7       −1340.45   p=0.005; q=0.05                                n/a              NA                                                                                                                                                              NA
  M8       −1318.69   p~0~=0.9; p=2.24; q=99; (p~1~=0.05); ω=15.63   43.52; P\<0.01   14S^[b](#tfn5-mmr-17-05-7131){ref-type="table-fn"}^; 54K^[b](#tfn5-mmr-17-05-7131){ref-type="table-fn"}^; 60D^[b](#tfn5-mmr-17-05-7131){ref-type="table-fn"}^   10D^[b](#tfn5-mmr-17-05-7131){ref-type="table-fn"}^; 12V^[a](#tfn4-mmr-17-05-7131){ref-type="table-fn"}^; 67E^[a](#tfn4-mmr-17-05-7131){ref-type="table-fn"}^; 77Q^[b](#tfn5-mmr-17-05-7131){ref-type="table-fn"}^

lnL, log-likelihood difference between the two models; 2Δl, twice the log-likelihood difference between the two models; the positively selected sites were identified with posterior probability ≥0.9 using empirical Bayes method.

Posterior probability ≥0.95

Posterior probability ≥0.99; NA, not allowed.

###### 

Site-specific tests for positive selection on human papillomavirus-56 L1.

  Models   InL        Estimates of parameters                                2Δl              L1 positively selected sites
  -------- ---------- ------------------------------------------------------ ---------------- ------------------------------------------------------
  M7       −2542.50   p=0.005; q=0.049                                       n/a              NA
  M8       −2531.74   p~0~=0.986; p=0.005; q=4.034; (p~1~=0.014); ω=10.537   21.51; P\<0.01   510K^[a](#tfn7-mmr-17-05-7131){ref-type="table-fn"}^

lnL, log-likelihood difference between the two models; 2Δl, twice the log-likelihood difference between the two models; the positively selected sites were identified with posterior probability ≥0.9 using empirical Bayes method.

Posterior probability ≥0.99; NA, not allowed.

[^1]: Contributed equally
